Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CURIS INCCRIS · Entity 8401 | Director | May 03, 2017 | May 05, 2017 |
| TITAN PHARMACEUTICALS INCTTNP · Entity 74432 | Director | January 28, 2022 | January 28, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CURIS INC
Report date May 03, 2017 · Filed May 05, 2017 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy JR & MW McNab Operating LP | 96,276 |
Reported balance
After 2017-05-03 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-05-03 · Sale · Disposed 30,000 · Balance 96,276 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan to sell 450,000 shares. F2: With this Form 4 filing, the plan is now complete. The cumulative total of 450,000 shares has been reached. F3: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $2.13 to $2.28, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. |
| Common StockSEC Table I · non-derivative | IndirectBy JR & MW McNab Operating LP | 66,176 |
Reported balance
After 2017-05-04 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2017-05-04 · Sale · Disposed 30,100 · Balance 66,176 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan to sell 450,000 shares. F2: With this Form 4 filing, the plan is now complete. The cumulative total of 450,000 shares has been reached. F4: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.92 to $2.21, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. |
| Common StockSEC Table I · non-derivative | IndirectBy JR & MW McNab Operating LP | 50,000 |
Reported balance
After 2017-05-05 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2017-05-05 · Sale · Disposed 16,176 · Balance 50,000 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan to sell 450,000 shares. F2: With this Form 4 filing, the plan is now complete. The cumulative total of 450,000 shares has been reached. F5: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.86 to $1.98, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. |
| Common StockSEC Table I · non-derivative | Direct | 879,688 |
Reported balance
Holding disclosure · report date 2017-05-03 · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · Balance 879,688 |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan to sell 450,000 shares.
F2: With this Form 4 filing, the plan is now complete. The cumulative total of 450,000 shares has been reached.
F3: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $2.13 to $2.28, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.
F4: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.92 to $2.21, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.
F5: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.86 to $1.98, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.
TITAN PHARMACEUTICALS INC
Report date January 28, 2022 · Filed January 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy JT Pharma | 51,021 |
Reported balance
After 2022-01-28 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-01-28 · Other · Acquired 51,021 · Balance 51,021 F1: Represents $50,000 of shares issued to JT Pharmaceuticals, Inc. ("JT") as a milestone payment under the October 2020 asset purchase agreement. Mr. McNab is a principal of JT and has voting and dispositive control of such shares. |
| Common StockSEC Table I · non-derivative | Direct | 1,669 |
Reported balance
Holding disclosure · report date 2022-01-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,669 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents $50,000 of shares issued to JT Pharmaceuticals, Inc. ("JT") as a milestone payment under the October 2020 asset purchase agreement. Mr. McNab is a principal of JT and has voting and dispositive control of such shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 28, 2022 Filed Jan 28, 2022 15:14 UTC | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | OtherCommon Stock | 51,021 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-008949 · tm221868-6_4seq1.xml · nonDerivative · entry 1 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JT Pharma Disclosed balance after: 51,021 F1 · kind: Represents $50,000 of shares issued to JT Pharmaceuticals, Inc. ("JT") as a milestone payment under the October 2020 asset purchase agreement. Mr. McNab is a principal of JT and has voting and dispositive control of such shares. F1 · price: Represents $50,000 of shares issued to JT Pharmaceuticals, Inc. ("JT") as a milestone payment under the October 2020 asset purchase agreement. Mr. McNab is a principal of JT and has voting and dispositive control of such shares. F1 · ownership.nature: Represents $50,000 of shares issued to JT Pharmaceuticals, Inc. ("JT") as a milestone payment under the October 2020 asset purchase agreement. Mr. McNab is a principal of JT and has voting and dispositive control of such shares. Read SEC document |
| January 05, 2022 Filed Jan 5, 2022 18:52 UTC | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | GrantOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001104659-22-001619 · tm221868-3_4seq1.xml · derivative · entry 1 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-01-05 Read SEC document |
| February 10, 2021 Filed Feb 11, 2021 06:29 UTC | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | GrantOption to Purchase Common Stock · Derivative | 25,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001104659-21-020185 · tm216217-4_4.xml · derivative · entry 1 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-02-10 Read SEC document |
| September 21, 2018 Filed Sep 25, 2018 19:04 UTC | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | GrantWarrants · Derivative | 200,000 | $0.00 Strike: $0.25 | $0.00 |
DisclosureSEC source: 0001144204-18-050780 · tv503426_4.xml · derivative · entry 2 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: common stock · 200,000 shares Expires 2023-09-25 Read SEC document |
| September 21, 2018 Filed Sep 25, 2018 19:04 UTC | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | PurchaseCommon Stock | 200,000 | $0.25 | $50,000.00 |
DisclosureSEC source: 0001144204-18-050780 · tv503426_4.xml · nonDerivative · entry 1 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 18:28 UTC | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | GrantOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001144204-17-048728 · v475386_4.xml · derivative · entry 1 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-09-15 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing as of September 1, 2017. Read SEC document |
| May 05, 2017 Filed May 5, 2017 21:34 UTC Amendment | CURIS INC CRIS · Entity 8401 | SaleCommon Stock | 16,176 | $1.90 | $30,721.46 |
DisclosureSEC source: 0001209191-17-030403 · doc4a.xml · nonDerivative · entry 3 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JR & MW McNab Operating LP Disclosed balance after: 50,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan to sell 450,000 shares. F2 · kind: With this Form 4 filing, the plan is now complete. The cumulative total of 450,000 shares has been reached. F5 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.86 to $1.98, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. Read SEC document |
| May 05, 2017 Filed May 5, 2017 20:30 UTC | CURIS INC CRIS · Entity 8401 | SaleCommon Stock | 16,176 | $1.90 | $30,721.46 |
DisclosureSEC source: 0001209191-17-030347 · doc4.xml · nonDerivative · entry 3 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JR & MW McNab Operating LP Disclosed balance after: 50,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.86 to $1.98, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. Read SEC document |
| May 04, 2017 Filed May 5, 2017 21:34 UTC Amendment | CURIS INC CRIS · Entity 8401 | SaleCommon Stock | 30,100 | $1.97 | $59,158.54 |
DisclosureSEC source: 0001209191-17-030403 · doc4a.xml · nonDerivative · entry 2 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JR & MW McNab Operating LP Disclosed balance after: 66,176 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan to sell 450,000 shares. F2 · kind: With this Form 4 filing, the plan is now complete. The cumulative total of 450,000 shares has been reached. F4 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.92 to $2.21, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. Read SEC document |
| May 04, 2017 Filed May 5, 2017 20:30 UTC | CURIS INC CRIS · Entity 8401 | SaleCommon Stock | 30,100 | $1.97 | $59,158.54 |
DisclosureSEC source: 0001209191-17-030347 · doc4.xml · nonDerivative · entry 2 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JR & MW McNab Operating LP Disclosed balance after: 66,176 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.92 to $2.21, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. Read SEC document |
| May 03, 2017 Filed May 5, 2017 21:34 UTC Amendment | CURIS INC CRIS · Entity 8401 | SaleCommon Stock | 30,000 | $2.18 | $65,544.00 |
DisclosureSEC source: 0001209191-17-030403 · doc4a.xml · nonDerivative · entry 1 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JR & MW McNab Operating LP Disclosed balance after: 96,276 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan to sell 450,000 shares. F2 · kind: With this Form 4 filing, the plan is now complete. The cumulative total of 450,000 shares has been reached. F3 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $2.13 to $2.28, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. Read SEC document |
| May 03, 2017 Filed May 5, 2017 20:30 UTC | CURIS INC CRIS · Entity 8401 | SaleCommon Stock | 30,000 | $2.18 | $65,544.00 |
DisclosureSEC source: 0001209191-17-030347 · doc4.xml · nonDerivative · entry 1 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JR & MW McNab Operating LP Disclosed balance after: 96,276 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $2.13 to $2.28, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. Read SEC document |
| May 02, 2017 Filed May 2, 2017 20:53 UTC | CURIS INC CRIS · Entity 8401 | SaleCommon Stock | 35,646 | $2.31 | $82,313.74 |
DisclosureSEC source: 0001209191-17-029242 · doc4.xml · nonDerivative · entry 3 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JR & MW McNab Operating LP Disclosed balance after: 126,276 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $2.26 to $2.39, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. Read SEC document |
| May 01, 2017 Filed May 2, 2017 20:53 UTC | CURIS INC CRIS · Entity 8401 | SaleCommon Stock | 38,113 | $2.38 | $90,708.94 |
DisclosureSEC source: 0001209191-17-029242 · doc4.xml · nonDerivative · entry 2 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JR & MW McNab Operating LP Disclosed balance after: 161,922 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $2.34 to $2.47, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. Read SEC document |
| April 28, 2017 Filed May 2, 2017 20:53 UTC | CURIS INC CRIS · Entity 8401 | SaleCommon Stock | 42,949 | $2.45 | $105,014.60 |
DisclosureSEC source: 0001209191-17-029242 · doc4.xml · nonDerivative · entry 1 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JR & MW McNab Operating LP Disclosed balance after: 200,035 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $2.40 to $2.53, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. Read SEC document |
| April 27, 2017 Filed Apr 27, 2017 20:58 UTC | CURIS INC CRIS · Entity 8401 | SaleCommon Stock | 37,202 | $2.57 | $95,624.02 |
DisclosureSEC source: 0001209191-17-028453 · doc4.xml · nonDerivative · entry 4 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JR & MW McNab Operating LP Disclosed balance after: 242,984 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $2.51 to $2.66, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. Read SEC document |
| April 26, 2017 Filed Apr 27, 2017 20:58 UTC | CURIS INC CRIS · Entity 8401 | SaleCommon Stock | 19,814 | $2.65 | $52,441.71 |
DisclosureSEC source: 0001209191-17-028453 · doc4.xml · nonDerivative · entry 3 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JR & MW McNab Operating LP Disclosed balance after: 280,186 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $2.57 to $2.695, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. Read SEC document |
| April 26, 2017 Filed Apr 27, 2017 20:58 UTC | CURIS INC CRIS · Entity 8401 | SaleCommon Stock | 32,738 | $2.65 | $86,647.66 |
DisclosureSEC source: 0001209191-17-028453 · doc4.xml · nonDerivative · entry 2 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 879,688 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $2.57 to $2.695, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 20:58 UTC | CURIS INC CRIS · Entity 8401 | SaleCommon Stock | 56,940 | $2.60 | $148,305.92 |
DisclosureSEC source: 0001209191-17-028453 · doc4.xml · nonDerivative · entry 1 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 912,426 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $2.55 to $2.63, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. Read SEC document |
| April 24, 2017 Filed Apr 24, 2017 21:03 UTC | CURIS INC CRIS · Entity 8401 | SaleCommon Stock | 42,076 | $2.56 | $107,861.83 |
DisclosureSEC source: 0001209191-17-027995 · doc4.xml · nonDerivative · entry 3 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,269,366 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $2.53 to $2.58, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. Read SEC document |
| April 24, 2017 Filed Apr 27, 2017 21:00 UTC Amendment | CURIS INC CRIS · Entity 8401 | SaleCommon Stock | 42,076 | $2.56 | $107,861.83 |
DisclosureSEC source: 0001209191-17-028456 · doc4a.xml · nonDerivative · entry 3 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 969,366 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $2.53 to $2.58, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. Read SEC document |
| April 21, 2017 Filed Apr 24, 2017 21:03 UTC | CURIS INC CRIS · Entity 8401 | SaleCommon Stock | 45,705 | $2.58 | $117,841.20 |
DisclosureSEC source: 0001209191-17-027995 · doc4.xml · nonDerivative · entry 2 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,311,442 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $2.53 to $2.65, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. Read SEC document |
| April 21, 2017 Filed Apr 27, 2017 21:00 UTC Amendment | CURIS INC CRIS · Entity 8401 | SaleCommon Stock | 45,705 | $2.58 | $117,841.20 |
DisclosureSEC source: 0001209191-17-028456 · doc4a.xml · nonDerivative · entry 2 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,011,442 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $2.53 to $2.65, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. Read SEC document |
| April 20, 2017 Filed Apr 24, 2017 21:03 UTC | CURIS INC CRIS · Entity 8401 | SaleCommon Stock | 22,541 | $2.66 | $59,979.35 |
DisclosureSEC source: 0001209191-17-027995 · doc4.xml · nonDerivative · entry 1 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,357,147 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $2.61 to $2.69, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. Read SEC document |
| April 20, 2017 Filed Apr 27, 2017 21:00 UTC Amendment | CURIS INC CRIS · Entity 8401 | SaleCommon Stock | 22,541 | $2.66 | $59,979.35 |
DisclosureSEC source: 0001209191-17-028456 · doc4a.xml · nonDerivative · entry 1 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,057,147 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $2.61 to $2.69, inclusive. The filer undertakes to provide to Curis Inc., any security holder of Curis, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 21:58 UTC | CURIS INC CRIS · Entity 8401 | GrantNon-qualified stock option · Derivative | 120,000 | $0.00 Strike: $2.31 | $0.00 |
DisclosureSEC source: 0001209191-17-016748 · doc4.xml · derivative · entry 1 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2027-02-27 F1 · derivative.exercise_date: Options granted under the 2010 Amended and Restated Stock Incentive Plan and 1/12th of the total shares will vest monthly beginning on January 1, 2017 until all of the shares underlying the award become vested on January 1, 2018, subject to the director's continued service with the Company. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 15:46 UTC | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | GrantOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001144204-17-010123 · v459918_4.xml · derivative · entry 1 MCNAB JAMES R · CIK 0001190126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-02-16 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.